Hers vs MangoRx: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

MangoRx beats Hers overall, scoring 7.5/10 vs 7.3/10. Hers is more affordable at $199/mo vs $299/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose MangoRx for users who want a multi-service telehealth platform covering .

A side-by-side comparison of Hers and MangoRx covering pricing, scores, medication types, insurance, and more to help you decide.

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Higher Rated

MangoRx

#27 of 48

7.5/10

Multi-service telehealth platform offering compounded GLP-1 alongside other health services.

Visit MangoRx

Feature	Hers	MangoRx
Our Score	7.3/10	7.5/10
Starting Price	$199/mo	$299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand	Users who want a multi-service telehealth platform covering weight loss and men's health
Ranking	#35	#27

Pros & Cons Compared

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

MangoRx

Pros

+Oral dissolving tablets exclusively — zero injections for any GLP-1 option
+Publicly traded on NASDAQ (MGRX) — SEC-required financial transparency that private competitors can't match
+Semaglutide tablet includes Vitamin B6 to help reduce nausea during treatment
+Free 100% online consultation with no video call required

Cons

−$299/mo for oral semaglutide is 2-3x the cost of injectable alternatives at $99-149/mo
−Early-stage public company with limited revenue — stock performance reflects financial uncertainty
−Only oral tablet format available — no injectable options if you want higher bioavailability

Our Verdict

MangoRx edges out Hers with a score of 7.5/10 vs 7.3/10. If budget is your priority, Hers starts at $199/mo compared to MangoRx's $299/mo. Hers offers both brand-name and compounded medications, giving you more flexibility. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose MangoRx if you want: users who want a multi-service telehealth platform covering weight loss and men's health.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Hers nor MangoRx feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review